ArticleJACC. Case reports2025
Cardiac Manifestations of Alkaptonuria: Aortic Valve Stenosis and Coronary Artery Disease in a 63-Year-Old Patient.
Article in JACC. Case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlkaptonuria is a rare autosomal recessive disorder characterized by homogentisic acid accumulation, leading to ochronosis and multisystemic manifestations including cardiovascular complications. CASE SUMMARY: A 63-year-old male with a known family history of alkaptonuria presented with dyspnea and severe aortic stenosis. Coronary angiography revealed diffuse, severe calcific coronary artery disease The patient underwent successful mechanical aortic valve replacement, revealing characteristic ochronotic pigmentation intraoperatively. DISCUSSION: Cardiovascular involvement in alkaptonuria, although rare, can cause sever valvular and coronary artery disease. Early recognition through biochemical testing and imaging is essential. Early-onset valvular disease should raise suspicion of underlying systemic disorders such as alkaptonuria. TAKE-HOME MESSAGES: Alkaptonuria, although primarily known for musculoskeletal and connective tissue involvement, can lead to significant cardiovascular complications. Routine screening with echocardiography and computed tomography coronary angiography should be considered in patients with alkaptonuria to detect early valvular and coronary artery disease in order to ensure timely intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.